BR112017019845A2 - novas composições antivirais para o tratamento da gripe - Google Patents

novas composições antivirais para o tratamento da gripe

Info

Publication number
BR112017019845A2
BR112017019845A2 BR112017019845-2A BR112017019845A BR112017019845A2 BR 112017019845 A2 BR112017019845 A2 BR 112017019845A2 BR 112017019845 A BR112017019845 A BR 112017019845A BR 112017019845 A2 BR112017019845 A2 BR 112017019845A2
Authority
BR
Brazil
Prior art keywords
antiviral compositions
new antiviral
treating flu
treating
flu
Prior art date
Application number
BR112017019845-2A
Other languages
English (en)
Other versions
BR112017019845B1 (pt
Inventor
Rosa-Calatrava Manuel
Terrier Olivier
Textoris Julien
Boivin Guy
Pizzorno Mario
Original Assignee
Universite Claude Bernard Lyon 1
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Hospices Civils De Lyon
Universite Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Claude Bernard Lyon 1, Institut National De La Sante Et De La Recherche Medicale (Inserm), Hospices Civils De Lyon, Universite Laval filed Critical Universite Claude Bernard Lyon 1
Publication of BR112017019845A2 publication Critical patent/BR112017019845A2/pt
Publication of BR112017019845B1 publication Critical patent/BR112017019845B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a presente invenção se refere a uma composição farmacêutica ou veterinária para a sua utilização na prevenção e/ou tratamento de infecção pelos vírus influenza. tal composição é caracterizada por conter, em um veículo farmacêutico apropriado, pelo menos um composto selecionado dentre etilefrina e diltiazem.
BR112017019845-2A 2015-03-19 2016-03-18 Novas composições antivirais para o tratamento da gripe BR112017019845B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1552284 2015-03-19
FR1552284A FR3033701B1 (fr) 2015-03-19 2015-03-19 Nouvelles compositions antivirales pour le traitement de la grippe
PCT/EP2016/056036 WO2016146836A2 (fr) 2015-03-19 2016-03-18 Nouvelles compositions antivirales pour le traitement de la grippe

Publications (2)

Publication Number Publication Date
BR112017019845A2 true BR112017019845A2 (pt) 2018-06-05
BR112017019845B1 BR112017019845B1 (pt) 2023-03-21

Family

ID=53514310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019845-2A BR112017019845B1 (pt) 2015-03-19 2016-03-18 Novas composições antivirais para o tratamento da gripe

Country Status (11)

Country Link
US (1) US11351180B2 (pt)
EP (1) EP3270968B1 (pt)
JP (1) JP6884112B2 (pt)
KR (1) KR102646962B1 (pt)
CN (2) CN107743402A (pt)
BR (1) BR112017019845B1 (pt)
CA (1) CA2979784C (pt)
FR (1) FR3033701B1 (pt)
HK (1) HK1249430A1 (pt)
IL (1) IL254548B (pt)
WO (1) WO2016146836A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3057773B1 (fr) * 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
FR3081325B1 (fr) * 2018-05-23 2020-10-09 Univ Claude Bernard Lyon Diltiazem pour son utilisation dans le traitement des infections microbiennes
KR102227147B1 (ko) * 2018-08-30 2021-03-12 한국화학연구원 이오노포어를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 보조제
CN112569209A (zh) * 2019-09-27 2021-03-30 盈科瑞（天津）创新医药研究有限公司 一种吸入用阿比多尔溶液及其制备方法
FR3106055B1 (fr) 2020-01-13 2022-01-28 Centre Nat Rech Scient Combinaison de diltiazem et autres agents antiviraux
CN111202724A (zh) * 2020-02-16 2020-05-29 江苏艾立康药业股份有限公司 一种阿比朵尔吸入干粉药物组合物及其制备方法
FR3108033B1 (fr) 2020-03-10 2023-04-21 Univ Claude Bernard Lyon COMPOSES ANTIVIRAUX ET LEURS COMBINAISONS POUR TRAITER L’INFECTION VIRALE PAR LE SARS-CoV-2

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3326089A1 (de) 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin Zur inhalation bestimmte darreichungsform von calcium-antagonisten
US4663354A (en) 1984-04-26 1987-05-05 Klinge Pharma Gmbh Use of etilefrin and etilefrin pivalate in the long term treatment of circulatory disorders not due to hypotonia
US4849412A (en) * 1986-06-05 1989-07-18 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections
IT1226301B (it) 1988-07-26 1990-12-27 Zambon Spa Processo per la preparazione di intermedi per la sintesi del diltiazem.
NL9000763A (nl) 1990-03-31 1991-10-16 Stamicarbon Werkwijze voor het bereiden van 1,5-benzothiazepine-derivaten.
IT1244878B (it) 1990-12-11 1994-09-12 Lusochimica Spa Processo per la preparazione del (+)-cis-3-(acetossi)-5-!2-( dimetilammino)etil!-2,3-diidro-2-(4-metossifenil)-1,5-benzotiazepin- 4-(5h)-one cloridrato
FI97725C (fi) 1995-02-17 1997-02-10 Orion Yhtymae Oy Menetelmä diltiatseemin valmistamiseksi
WO2002094238A1 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
WO2005007082A2 (en) * 2003-06-03 2005-01-27 Wisys Technology Foundation, Inc. Treatment of chronic bacterial infection
JP5519906B2 (ja) * 2004-04-22 2014-06-11 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー 肝臓疾患の支持療法
EP1970061A4 (en) 2005-12-28 2009-04-08 Zakrytoe Aktsionernoe Obschest MEDICINE PRODUCT FOR THE TREATMENT OF VIRUS INFECTIONS
KR20090006062A (ko) 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 인플루엔자 바이러스 감염의 치료 방법
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
FR2953410B1 (fr) 2009-12-09 2012-02-24 Univ Claude Bernard Lyon Compositions antivirales pharmaceutiques ou veterinaires
JP2013139391A (ja) * 2010-04-09 2013-07-18 Hokkaido Univ ウイルス感染抑制および／または感染症治療剤
CN102657621B (zh) 2012-04-28 2013-11-13 天津金耀集团有限公司 注射用盐酸地尔硫卓冻干粉针剂

Also Published As

Publication number Publication date
CN113876781A (zh) 2022-01-04
EP3270968B1 (fr) 2024-03-06
US20180042937A1 (en) 2018-02-15
JP6884112B2 (ja) 2021-06-09
HK1249430A1 (zh) 2018-11-02
CN107743402A (zh) 2018-02-27
US11351180B2 (en) 2022-06-07
CA2979784A1 (fr) 2016-09-22
IL254548B (en) 2022-04-01
EP3270968A2 (fr) 2018-01-24
FR3033701A1 (fr) 2016-09-23
CA2979784C (fr) 2024-01-09
BR112017019845B1 (pt) 2023-03-21
FR3033701B1 (fr) 2021-01-15
KR20180006370A (ko) 2018-01-17
WO2016146836A2 (fr) 2016-09-22
IL254548A0 (en) 2017-11-30
JP2018508587A (ja) 2018-03-29
KR102646962B1 (ko) 2024-03-12
WO2016146836A3 (fr) 2016-11-03

Similar Documents

Publication Publication Date Title
BR112017019845A2 (pt) novas composições antivirais para o tratamento da gripe
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
BR112019007931A2 (pt) composições antivirais para o tratamento de infecções ligadas ao coronavírus
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
CL2017000309A1 (es) Indoles para su uso en la infección por el virus de la gripe
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2015003370A1 (es) Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2014001956A1 (es) Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas.
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
BR112018068341A2 (pt) 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
CL2014000311A1 (es) Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio.
CL2018001960A1 (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza.
CR20170005A (es) Derivados de insoindolina
BR112016012599A2 (pt) composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus
UY36221A (es) Derivados de isoindolinona
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
CL2015000362A1 (es) Compuestos derivados de tris-(hetero)aril-pirazoles; procedimiento de preparacion; medicamento; y su uso para el tratamiento y/o profilaxis de infecciones con retrovirus, en especial vih
PH12017501943A1 (en) Influenza virus neutralizing peptidomimetic compounds
BR112019002132A2 (pt) composições anti-retrovirais

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2016, OBSERVADAS AS CONDICOES LEGAIS